Mezzion

Mezzion Mezzion is a rare disease pharmaceutical company dedicated to improving outcomes for people living with single ventricle heart disease and Fontan physiology.

Mezzion focuses on delivering hope to the Fontan community through innovation and new treatments.

Meet Letitia: an aspiring occupational therapist with a vision for the future of cardiac care. Letitia started her CHD a...
03/15/2024

Meet Letitia: an aspiring occupational therapist with a vision for the future of cardiac care. Letitia started her CHD advocacy journey as a college freshman after meeting other Fontan patients with similar congenital heart defects for the first time. Check out Letitia’s story on Mezzion’s Faces of Fontan series.

Letitia

03/06/2024

Oftentimes we talk about how common congenital heart disease is at 1 in 100 individuals being born with CHD. However, single ventricle disease is considered rare, affecting approximately 5 in every 100,000 newborns. I actually didn’t realize it was that few newborns until I just looked up the statistic.

There are many important reasons to highlight the fact that single ventricle disease is a rare disease, including: advocacy, awareness, research & innovation, and public health. Within these different buckets, there are a plethora of areas and topics covered, such as regulatory pathways for new rare disease treatment options - another reason to pay attention to the FUEL2 trial, even if you aren’t within the inclusion criteria for the current study. It’s a pathway for treatment options, more awareness, increased funding opportunities, additional research, and so much more. It is so important to stay informed and engaged with what is going on within the community, even if it doesn’t immediately include your specific needs. Your voice, experiences and presence create the awareness for your needs and disease state - you’d be surprised how many times priorities shift because of one person who spoke up.

I’m sharing all of this to say, “Happy Rare Disease Day!”

Check out our latest press release: Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and...
03/05/2024

Check out our latest press release: Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as the Global Principal Investigator for the Confirmatory Pivotal Phase 3 Trial FUEL-2.

/PRNewswire/ -- Mezzion Pharmaceuticals is a rare disease company conducting the confirmatory pivotal phase 3 clinical trial in Fontan subjects: The Fontan...

Meet Katherine: from dancer to full-time chef, Katherine has not let single ventricle heart disease stop her from pursui...
03/04/2024

Meet Katherine: from dancer to full-time chef, Katherine has not let single ventricle heart disease stop her from pursuing her passions despite the challenges. Katherine shares what a treatment option could mean for her ability to fully achieve her personal and professional dreams. Check out Katherine’s story on Mezzion’s Faces of Fontan series.

Katherine

Meet Kyleigh: an avid mentor living with a single ventricle heart defect. She shares her experience of managing her cond...
03/01/2024

Meet Kyleigh: an avid mentor living with a single ventricle heart defect. She shares her experience of managing her condition while mentoring young children, and why she is committed to better outcomes for future generations of patients. Check out Kylie’s story on Mezzion’s Faces of Fontan series.

Kyleigh

Mezzion is proud to have secured a nearly $40M USD investment last year that was critical for our late-stage clinical de...
02/29/2024

Mezzion is proud to have secured a nearly $40M USD investment last year that was critical for our late-stage clinical development program. This clinical program is part of our commitment to bring forward the first approved treatment option for people living with single ventricle heart disease and Fontan physiology.

/PRNewswire/ -- Mezzion Pharma ("Mezzion"), a rare disease focused pharmaceutical company, announced that it has secured nearly $40M USD to fund FUEL-2, their...

Mezzion was a proud sponsor of the 8th World Congress of Pediatric Cardiology and Cardiac Surgery. From fascinating conv...
02/28/2024

Mezzion was a proud sponsor of the 8th World Congress of Pediatric Cardiology and Cardiac Surgery. From fascinating conversations at our booth to hosting a celebration of the launch of the FUEL-2 clinical trial, we were inspired by the hundreds of physicians, patients, professionals, and advocates united for better pediatric and congenital heart disease care.

Meet Meghan Roswick-Didier: HLHS: mother, adventurer, and advocacy leader living with a single ventricle heart defect. S...
02/28/2024

Meet Meghan Roswick-Didier: HLHS: mother, adventurer, and advocacy leader living with a single ventricle heart defect. She shares her journey and motivation to fight for expanded treatment options. Check out Meghan’s story on Mezzion’s Faces of Fontan series.

Meghan

As part of our mission to help those living with single ventricle heart disease and Fontan circulation, Mezzion is curre...
02/27/2024

As part of our mission to help those living with single ventricle heart disease and Fontan circulation, Mezzion is currently conducting FUEL-2, the world's largest Fontan clinical trial. Learn more about our Udenafil (PDE5) clinical program.

Now Enrolling:Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 (FUEL-2) Get Started The FUEL-2 Study is a phase 3, double-blind, placebo-controlled study researching the efficacy and safety of an investigational medication, udenafil, for teenagers 12–18 years of age who had the Fontan pr...

Single ventricle heart disease is a rare congenital heart disease where a person is born with one functional lower heart...
02/27/2024

Single ventricle heart disease is a rare congenital heart disease where a person is born with one functional lower heart chamber, or ventricle, instead of two. The one ventricle must do the job of two—pumping deoxygenated blue blood to the lungs and oxygenated red blood to the body. This requires surgical interventions to redirect the flow of blood.

Although there is currently no cure, one treatment option for those living with single ventricle heart disease is the Fontan procedure, a surgery that improves circulation by rerouting deoxygenated blue blood to flow directly to the lungs. To learn more about single ventricle heart disease visit: https://mezzion.com/understanding-svhd

02/27/2024

Fontan patients and families: have you heard about the world’s largest Fontan clinical trial? Learn more about FUEL-2, a Mezzion Pharmaceuticals clinical trial investigating the clinical efficacy and safety of Udenafil in teenagers 12-18 years of age who have undergone the Fontan procedure. ​​​​​​​​​​​​​​​​​​Those interested in learning more about FUEL-2, including why the study is being conducted, what it entails, and how to sign up for potential enrollment, are encouraged to attend the upcoming FUEL-2 information sessions.

Sessions will be hosted via Zoom webinar on Thursday, February22, 8 pm ET / 7 pm CT, Tuesday, February 27, 8 pm ET / 7 pm CT and Thursday, March 7, 8 pm ET / 7 pm CT. Register here for an information session: https://bit.ly/3Ujald1

More information, including how to easily sign up for potential enrollment can always be found at FUEL2study.com for anyone who cannot attend.

Mezzion is a rare disease pharmaceutical company dedicated to improving outcomes for people living with single ventricle...
02/12/2024

Mezzion is a rare disease pharmaceutical company dedicated to improving outcomes for people living with single ventricle heart disease and Fontan physiology. Mezzion focuses on discovering, developing, and delivering hope to the Fontan community through innovation and new treatment options. Visit https://mezzion.com/ to learn more.

Launching the world’s largest Fontan clinical trial Learn More about FUEL-2 Shaping the future of the Fontan community Discover our Commitments Leading with science and passion in everything we do Meet our Leadership Team Shaping the future of the Fontan community We strive to discover, develop an...

Address

Deerfield, IL

Alerts

Be the first to know and let us send you an email when Mezzion posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Mezzion:

Share